Clinical Trial Update: Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure [Phase 3]

View source ↗

Summary

Phase 3 trial investigating predictive factors for an additional 10% reduction of intra-ocular pressure in glaucoma and ocular hypertension patients; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Primary Open Angle
• Ocular Hypertension

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Glaucoma, Primary Open Angle (POAG), Ocular Hypertension | Phase 3 | Status: COMPLETED